Leenstra James L, Rodriguez Fausto J, Frechette Christina M, Giannini Caterina, Stafford Scott L, Pollock Bruce E, Schild Steven E, Scheithauer Bernd W, Jenkins Robert B, Buckner Jan C, Brown Paul D
Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54. doi: 10.1016/j.ijrobp.2006.10.018. Epub 2006 Dec 21.
To examine the outcomes of patients with histologically confirmed central neurocytomas.
The data from 45 patients with central neurocytomas diagnosed between 1971 and 2003 were retrospectively evaluated. Various combinations of surgery, radiotherapy (RT), and chemotherapy had been used for treatment.
The median follow-up was 10.0 years. The 10-year overall survival and local control rate was 83% and 60%, respectively. Patients whose tumor had a mitotic index of <3 (per 10 high-power fields) experienced a 10-year survival and local control rate of 89% and 74%, respectively, compared with 57% (p = 0.040) and 46% (p = 0.14) for patients with a tumor mitotic index of > or =3. The 10-year survival and local control rate was 90% and 74% for patients with typical tumors compared with 63% (p = 0.055) and 46% (p = 0.41) for those with atypical tumors. A comparison of gross total resection with subtotal resection showed no significant difference in survival or local control. Postoperative RT improved local control at 10 years (75% with RT vs. 51% without RT, p = 0.045); however, this did not translate into a survival benefit. No 1p19q deletions were found in the 19 tumors tested.
Although the overall prognosis is quite favorable, one-third of patients experienced tumor recurrence or progression at 10 years, regardless of the extent of the initial resection. Postoperative RT significantly improved local control but not survival, most likely because of the effectiveness of salvage RT. For incompletely resected atypical tumors and/or those with a high mitotic index, consideration should be given to adjuvant RT because of the more aggressive nature.
研究经组织学确诊的中枢神经细胞瘤患者的预后情况。
回顾性评估1971年至2003年间诊断为中枢神经细胞瘤的45例患者的数据。治疗采用了手术、放疗(RT)和化疗的各种组合。
中位随访时间为10.0年。10年总生存率和局部控制率分别为83%和60%。肿瘤有丝分裂指数<3(每10个高倍视野)的患者10年生存率和局部控制率分别为89%和74%,而有丝分裂指数≥3的患者分别为57%(p = 0.040)和46%(p = 0.14)。典型肿瘤患者的10年生存率和局部控制率分别为90%和74%,非典型肿瘤患者分别为63%(p = 0.055)和46%(p = 0.41)。大体全切除与次全切除的比较显示,生存率或局部控制率无显著差异。术后放疗提高了10年的局部控制率(放疗组为75%,未放疗组为51%,p = 0.045);然而,这并未转化为生存获益。在检测的19个肿瘤中未发现1p19q缺失。
尽管总体预后相当良好,但无论初始切除范围如何,三分之一的患者在10年时出现肿瘤复发或进展。术后放疗显著提高了局部控制率,但未提高生存率,这很可能是因为挽救性放疗的有效性。对于不完全切除的非典型肿瘤和/或有高有丝分裂指数的肿瘤,由于其侵袭性更强,应考虑辅助放疗。